Vaxxinity concludes subject enrolment in Phase III Covid-19 vaccine trial

Vaxxinity has concluded subject enrolment in its Phase III pivotal clinical trial of Covid-19 vaccine, UB-612, as a heterologous booster.

UB-612 is being analysed as a booster following an initial regimen with messenger ribonucleic acid (mRNA), adeno-vectored, and inactivated vaccines.